UPDATE 1-Pfizer study shows COVID-19 booster can be given along with pneumonia shot

By

By Reuters Staff

(Reuters) - Pfizer Inc said on Wednesday booster doses of its COVID-19 vaccine can be administered along with its pneumonia vaccine and produced strong safety and immune responses in people aged 65 and older in a late-stage study.

The study, initiated in May, tested the company's next-generation pneumococcal conjugate vaccine, PREVNAR 20, with a third dose of the Pfizer-BioNTech COVID-19 shot in 570 participants.

The aim of the study was to test the safety of the combination and the immune response after adding the pneumonia vaccine to the existing COVID-19 vaccine.

The company said responses elicited by PREVNAR 20 and booster dose of the COVID-19 vaccine were similar when given together or with placebo.

The data provides evidence supporting the potential to administer PREVNAR 20 and the company's COVID-19 vaccine at the same time, reducing the number of visits people make to doctors or pharmacies for recommended immunization, Pfizer said in a statement (https://bit.ly/3zTyH0J).

PREVNAR 20 was approved by the U.S. Food and Drug Administration in June last year to help protect adults against most invasive pneumococcal diseases and pneumonia.

Study participants were recruited from the companies' late-stage COVID-19 vaccine study, and those who had received the second dose of the company's COVID-19 vaccine at least six months before entering the co-administration study.

Related Articles

UPDATE 1-U.S. suicide hotline 988 is set to go live, but many states may not be ready

(Adds Lifeline calls in Washington and Wyoming, paragraph 10) By Barbara Goldberg NEW YORK (Reuters) - In just six months, 988 goes live as the shortcut to call or text the U.S. suicide hotline at a Read More »

COLUMN-A quiet experiment is testing broader privatization of U.S. Medicare

(The opinions expressed here are those of the author, a columnist for Reuters.) By Mark Miller (Reuters) - Millions of retirees have opted out of traditional Medicare over the past two decades, Read More »

EMA lists rare spinal condition as side effect of AstraZeneca's COVID-19 shot

By Reuters Staff (Reuters) - A safety panel of the European drug regulator on Friday recommended adding a rare spinal inflammation called transverse myelitis as a side effect of AstraZeneca's COVID-19 Read More »